An open‐label phase 2 trial of entospletinib in indolent non‐Hodgkin lymphoma and mantle cell lymphoma

Spleen tyrosine kinase (Syk) mediates B‐cell receptor signalling in normal and malignant B cells. Entospletinib is an oral, selective Syk inhibitor. Entospletinib monotherapy was evaluated in a multicentre, phase 2 study of patients with relapsed or refractory indolent non‐Hodgkin lymphoma or mantle...

Descripción completa

Detalles Bibliográficos
Autores principales: Andorsky, David J., Kolibaba, Kathryn S., Assouline, Sarit, Forero‐Torres, Andres, Jones, Vicky, Klein, Leonard M., Patel‐Donnelly, Dipti, Smith, Mitchell, Ye, Wei, Shi, Wen, Yasenchak, Christopher A., Sharman, Jeff P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Haematological Malignancy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585960/
https://www.ncbi.nlm.nih.gov/pubmed/30183069
http://dx.doi.org/10.1111/bjh.15552

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6585960/
https://www.ncbi.nlm.nih.gov/pubmed/30183069
http://dx.doi.org/10.1111/bjh.15552

Ejemplares similares